Publications by authors named "Peter Vestergaard Rasmussen"

Claim this Profile
P
Patient's and researcher's perspectives on patient involvement in research in multiple sclerosis.
Julie Schjødtz Hansen, Peter Vestergaard Rasmussen, Nanna Brix Finnerup, Kristina Bacher Svandsen

Dan Med J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric Onset Multiple Sclerosis (POMS): Exploring phenotypic characterization and pubertal influences in modulating the disease activity from the Danish MS Registry (DMSR).
Silvy Pilotto, Luigi Pontieri, Helle Hvilsted Nielsen, Peter Vestergaard Rasmussen, Kristina Bacher Svendsen

Mult Scler· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark.
Elisabeth Framke, Finn Sellebjerg, Matthias Kant, Morten Stilund, Henrik Boye Jensen, Peter Vestergaard Rasmussen

Mult Scler· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns and predictors of multiple sclerosis phenotype transition.
Luigi Pontieri, Nupur Greene, Malthe Faurschou Wandall-Holm, Svend Sparre Geertsen, Nasrin Asgari, Peter Vestergaard Rasmussen

Brain Commun· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differentiation of MS lesions through analysis of microvascular distribution.
Linda Sundvall, Irene Klærke Mikkelsen, Simon F Eskildsen, Mette Madsen Hjørringgaard, Mikkel Nygaard, Peter Vestergaard Rasmussen

Imaging Neurosci (Camb)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shedding Light on the Black Box of Rehabilitation: Differential Short- and Long-Term Effects of Multidisciplinary Multiple Sclerosis Rehabilitation.
Philipp Trénel, Finn Boesen, Anders Guldhammer Skjerbæk, Thor Petersen, Peter Vestergaard Rasmussen

Int J MS Care· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telecoaching of Individuals With Multiple Sclerosis After Inpatient Multidisciplinary Rehabilitation: The Danish MS Hospitals Rehabilitation Study.
Michael Nørgaard, Finn Boesen, Anders Guldhammer Skjerbæk, Ellen Jensen, Jeanne Hansen, Peter Vestergaard Rasmussen

Int J MS Care· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial.
Julie Schjødtz Hansen, Fernando Boix, Jørgen Bo Hasselstrøm, Lambert Kristiansen Sørensen, Mads Kjolby, Peter Vestergaard Rasmussen

Clin Transl Sci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of treatment switching in the Big Multiple Sclerosis Data Network.
Tim Spelman, Melinda Magyari, Helmut Butzkueven, Anneke Van Der Walt, Sandra Vukusic, Peter Vestergaard Rasmussen

Front Neurol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Izanne Roos, Stella Hughes, Gavin McDonnell, Charles B Malpas, Sifat Sharmin, Peter Vestergaard Rasmussen

JAMA Neurol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial.
Julie Schjødtz Hansen, Stefan Gustavsen, Homayoun Roshanisefat, Matthias Kant, Fin Biering-Sørensen, Peter Vestergaard Rasmussen

Pharmaceuticals (Basel)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natalizumab treatment of multiple sclerosis - a Danish nationwide study with 13 years of follow-up.
Mathias Due Buron, Jeppe Romme Christensen, Luigi Pontieri, Hanna Joensen, Matthias Kant, Peter Vestergaard Rasmussen

Mult Scler Relat Disord· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
Per Soelberg Sorensen, Luigi Pontieri, Hanna Joensen, Alex Heick, Peter Vestergaard Rasmussen

Mult Scler Relat Disord· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Viktoria Papp, Mathias Due Buron, Volkert Siersma, Peter Vestergaard Rasmussen, Zsolt Illes

PLoS One· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, Emmanuelle Leray, Dana Horakova, Peter Vestergaard Rasmussen

CNS Drugs· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
Tine Iskov Kopp, Stephan Bramow, Zsolt Illes, Matthias Kant, Claudia Kristensen, Peter Vestergaard Rasmussen

Mult Scler Relat Disord· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
Tim Spelman, Melinda Magyari, Fredrik Piehl, Anders Svenningsson, Peter Vestergaard Rasmussen

JAMA Neurol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial.
Julie Schjødtz Hansen, Rikke Middelhede Hansen, Thor Petersen, Stefan Gustavsen, Annette Bang Oturai, Peter Vestergaard Rasmussen

Brain Sci· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
Finn Boesen, Michael Nørgaard, Anders Guldhammer Skjerbæk, Peter Vestergaard Rasmussen, Thor Petersen

Mult Scler· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
Mathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg, Ismael Barzinji, Bech Danny, Peter Vestergaard Rasmussen

Neurology· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Qualitative factors shaping MS patients' experiences of infusible disease-modifying drugs: a critical incident technique analysis.
Janni Lisander Larsen, Jakob Schäfer, Helle Hvilsted Nielsen, Peter Vestergaard Rasmussen

BMJ Open· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International consensus on quality standards for brain health-focused care in multiple sclerosis.
Jeremy Hobart, Amy Bowen, George Pepper, Harriet Crofts, Lucy Eberhard, Peter Vestergaard Rasmussen

Mult Scler· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? The Danish MS hospitals rehabilitation study.
Anders Guldhammer Skjerbæk, Finn Boesen, Thor Petersen, Peter Vestergaard Rasmussen, Egon Stenager

Mult Scler· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.
Mathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg, Jette Frederiksen, Monika Katarzyna Góra, Peter Vestergaard Rasmussen

Neurology· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient awareness about family planning represents a major knowledge gap in multiple sclerosis.
Peter Vestergaard Rasmussen, Melinda Magyari, Julie Yoon Moberg, Mette Bøgelund, Ulla Fie Appel Jensen

Mult Scler Relat Disord· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis